Interleukin-12. Opportunities for the treatment of bladder cancer.
Urol Clin North Am
; 27(1): 147-55, 2000 Feb.
Article
en En
| MEDLINE
| ID: mdl-10696253
ABSTRACT
Despite incomplete understanding of the human immune system, the rapid progress in tumor immunology provides a framework for more effective and safe interventions in the near future. Early approaches in patients with cancer that have focused on the nonspecific and broad stimulation of the immune system by interferons and IL-12 will be replaced by the highly specific stimulation of immune reactions targeting precisely defined tumor antigens. IL-12 has several biologic properties that seem useful in immune therapy for bladder cancer. The striking antitumor responses with IL-12 in preclinical animal models of bladder cancer provide optimism that future clinical trials involving this agent may impact on the risk and mortality associated with this disease.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Adyuvantes Inmunológicos
/
Interleucina-12
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Año:
2000
Tipo del documento:
Article